コンテンツへスキップ
Merck
  • Comparison of pre-treatment and post-treatment use of selenium in retinal ischemia reperfusion injury.

Comparison of pre-treatment and post-treatment use of selenium in retinal ischemia reperfusion injury.

International journal of ophthalmology (2015-05-06)
Alper Yazici, Hasan Aksit, Esin Sogutlu Sari, Arzu Yay, Haydar Ali Erken, Dilek Aksit, Harun Cakmak, Kamil Seyrek, Sitki Samet Ermis
要旨

To investigate the effects of selenium in rat retinal ischemia reperfusion (IR) model and compare pre-treatment and post-treatment use. Selenium pre-treatment group (n=8) was treated with intraperitoneal (i.p.) selenium 0.5 mg/kg for 7d and terminated 24h after the IR injury. Selenium post-treatment group (n=8) was treated with i.p. selenium 0.5 mg/kg for 7d after the IR injury with termination at the end of the 7d period. Sham group (n=8) received i.p. saline injections identical to the selenium volume for 7d with termination 24h after the IR injury. Control group (n=8) received no intervention. Main outcome measures were retina superoxide dismutase (SOD), glutathione (GSH), total antioxidant status (TAS), malondialdehyde (MDA), DNA fragmentation levels, and immunohistological apoptosis evaluation. Compared to the Sham group, selenium pre-treatment had a statistical difference in all parameters except SOD. Post-treatment selenium also resulted in statistical differences in all parameters except the MDA levels. When comparing selenium groups, the pre-treatment selenium group had a statistically higher success in reduction of markers of cell damage such as MDA and DNA fragmentation. In contrast, the post-selenium treatment group had resulted in statistically higher levels of GSH. Histologically both selenium groups succeeded to limit retinal thickening and apoptosis. Pre-treatment use was statistically more successful in decreasing apoptosis in ganglion cell layer compared to post-treatment use. Selenium was successful in retinal protection in IR injuries. Pre-treatment efficacy was superior in terms of prevention of tissue damage and apoptosis.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
L-グルタチオン、還元型, suitable for cell culture, BioReagent, ≥98.0%, powder
Sigma-Aldrich
亜セレン酸ナトリウム, BioReagent, suitable for cell culture, ≥98%
Sigma-Aldrich
セレン, powder, −100 mesh, 99.99% trace metals basis
Sigma-Aldrich
亜セレン酸ナトリウム, 99%
Sigma-Aldrich
セレン, powder, −100 mesh, ≥99.5% trace metals basis
Sigma-Aldrich
亜セレン酸ナトリウム, γ-irradiated, lyophilized powder, BioXtra, suitable for cell culture
Sigma-Aldrich
L-グルタチオン、還元型, ≥98.0%
Sigma-Aldrich
セレン, pellets, <5 mm particle size, ≥99.999% trace metals basis
Sigma-Aldrich
セレン, pellets, <5 mm, ≥99.99% trace metals basis
Supelco
グルタチオン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-グルタチオン、還元型, BioXtra, ≥98.0%
Sigma-Aldrich
亜セレン酸ナトリウム, anhydrous, ≥90.0% (RT)
セレン, foil, 25x25mm, thickness 3mm, 99.95%
L-グルタチオン、還元型, European Pharmacopoeia (EP) Reference Standard
セレン, pellets, < 5mm, ≥99.999%
Sigma-Aldrich
亜セレン酸ナトリウム, SAJ first grade, ≥90.0%
Sigma-Aldrich
亜セレン酸ナトリウム, JIS special grade, ≥97.0%